SLC5A2 and heart failure: The study demonstrated that patients receiving anthracycline-based chemotherapy who were concurrently treated with SGLT2 inhibitors exhibited significantly lower rates of heart failure hospitalizations compared to those not receiving SGLT2i therapy.